

Heather H Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3048978/publications.pdf>

Version: 2024-02-01

81
papers

9,960
citations

172457
29
h-index

64796
79
g-index

85
all docs

85
docs citations

85
times ranked

15232
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660
2	MicroRNA profiling: approaches and considerations. <i>Nature Reviews Genetics</i> , 2012, 13, 358-369.	16.3	1,453
3	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 443-453.	27.0	1,205
4	Quantitative and stoichiometric analysis of the microRNA content of exosomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14888-14893.	7.1	880
5	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 134-143.	4.9	299
6	Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels. <i>PLoS ONE</i> , 2013, 8, e64795.	2.5	258
7	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 4492-4505.	8.2	250
8	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 69, 992-995.	1.9	228
9	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020, 38, 2798-2811.	1.6	170
10	Circulating microRNA Profiling Identifies a Subset of Metastatic Prostate Cancer Patients with Evidence of Cancer-Associated Hypoxia. <i>PLoS ONE</i> , 2013, 8, e69239.	2.5	147
11	lazarus Is a Novel pbx Gene that Globally Mediates hox Gene Function in Zebrafish. <i>Molecular Cell</i> , 2000, 6, 255-267.	9.7	134
12	Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. <i>European Urology</i> , 2019, 76, 452-458.	1.9	109
13	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417.	1.6	102
14	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , 2018, 73, 687-693.	1.9	99
15	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 362-373.	10.7	97
16	Germline and Somatic Mutations in Prostate Cancer for the Clinician. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 515-521.	4.9	91
17	Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <i>JAMA Oncology</i> , 2021, 7, 107.	7.1	90
18	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0198389.	2.5	86

#	ARTICLE	IF	CITATIONS
19	Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 122-127.	3.9	78
20	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. <i>Oncotarget</i> , 2016, 7, 82504-82510.	1.8	64
21	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. <i>PLoS ONE</i> , 2020, 15, e0233260.	2.5	63
22	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	47
23	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1601-1608.	1.6	44
24	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	1.9	42
25	Inherited TP53 Variants and Risk of Prostate Cancer. <i>European Urology</i> , 2022, 81, 243-250.	1.9	40
26	Glucocorticoids and prostate cancer treatment: friend or foe?. <i>Asian Journal of Andrology</i> , 2014, 16, 354.	1.6	37
27	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	2.9	35
28	Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. <i>Advances in Urology</i> , 2013, 2013, 1-6.	1.3	34
29	Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 222-227.	2.5	33
30	Ethnic disparities among men with prostate cancer undergoing germline testing. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 80.e1-80.e7.	1.6	32
31	Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. <i>JCI Insight</i> , 2019, 4, .	5.0	30
32	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 433-439.	2.3	29
33	Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. <i>Prostate</i> , 2018, 78, 121-127.	2.3	28
34	Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 372-381.	3.8	25
35	Genetic Testing in Prostate Cancer. <i>Current Oncology Reports</i> , 2020, 22, 5.	4.0	25
36	Prostate Cancer Screening in a New Era of Genetics. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 625-628.	1.9	24

#	ARTICLE	IF	CITATIONS
37	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	1.6	24
38	Disparities in germline testing among racial minorities with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 403-410.	3.9	22
39	Advanced Clinical States in Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 561-571.	1.8	21
40	A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. <i>Prostate</i> , 2016, 76, 1303-1311.	2.3	21
41	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	1.9	21
42	Genetic and Biochemical Analyses of Receptor and Cofactor Determinants for T-Cell-Tropic Feline Leukemia Virus Infection. <i>Journal of Virology</i> , 2002, 76, 8069-8078.	3.4	20
43	Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 287-291.	1.9	20
44	Barriers and facilitators of germline genetic evaluation for prostate cancer. <i>Prostate</i> , 2021, 81, 754-764.	2.3	19
45	Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. <i>Prostate</i> , 2019, 79, 701-708.	2.3	18
46	Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	3.0	17
47	Polyclonal <i>BRCA2</i> Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-5.	3.0	16
48	Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. <i>Bladder Cancer</i> , 2020, 6, 71-81.	0.4	16
49	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	3.0	14
50	Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2020, 38, 3740-3742.	1.6	14
51	Feline leukemia virus T entry is dependent on both expression levels and specific interactions between cofactor and receptor. <i>Virology</i> , 2007, 359, 170-178.	2.4	13
52	Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 144-154.	1.9	13
53	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6001-6011.	7.0	13
54	CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. <i>Molecular Therapy</i> , 2020, 28, 1238-1250.	8.2	12

#	ARTICLE	IF	CITATIONS
55	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 77.	2.5	11
56	Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity. <i>Clinical Cancer Research</i> , 2020, 26, 2439-2440.	7.0	11
57	Envelope Determinants for Dual-Receptor Specificity in Feline Leukemia Virus Subgroup A and T Variants. <i>Journal of Virology</i> , 2006, 80, 1619-1628.	3.4	10
58	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline <i>ATM</i> versus <i>BRCA2</i> mutations. <i>Prostate</i> , 2021, 81, 1382-1389.	2.3	10
59	Nonresponse to Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 210-213.	1.9	9
60	The resounding effect of DNA repair deficiency in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 385-388.	1.6	9
61	Germline genetics of prostate cancer. <i>Prostate</i> , 2022, 82, .	2.3	8
62	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017, 77, 1478-1488.	2.3	7
63	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. <i>Bladder Cancer</i> , 2019, 5, 289-298.	0.4	7
64	Adopting Consensus Terms for Testing in Precision Medicine. <i>JCO Precision Oncology</i> , 2021, 5, 1563-1567.	3.0	7
65	Long-Term Survival in Bone-Predominant Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e241-e244.	1.9	6
66	Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239686.	2.5	6
67	<i>BRCA2</i> Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series. <i>JCO Precision Oncology</i> , 2022, , .	3.0	6
68	Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1150-1155.	4.9	5
69	Hepatitis C infection and chemotherapy toxicity. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 474-480.	0.9	4
70	Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 486-493.	3.9	4
71	Technology-enhanced Acceleration of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. <i>Contemporary Clinical Trials</i> , 2022, 119, 106821.	1.8	4
72	Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015, 8, 51.	17.0	2

#	ARTICLE	IF	CITATIONS
73	Implementation of systematic germline genetic testing (GT) for metastatic prostate cancer (mPC) patients at the Puget Sound VA prostate oncology clinic.. Journal of Clinical Oncology, 2020, 38, 1578-1578.	1.6	2
74	Germline Testing in Prostate Cancer: When and Who to Test. Oncology, 2021, 35, 645-653.	0.5	2
75	Germline contributions to metastatic prostate cancer. Canadian Journal of Urology, 2019, 26, 19-21.	0.0	2
76	A Patient-Centered Approach to Research Prioritization in Prostate Cancer. Journal of Urology, 2022, 208, 277-283.	0.4	2
77	Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 496.e1-496.e8.	1.6	1
78	Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate, 2018, 78, 1077-1083.	2.3	0
79	Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 352.e19-352.e24.	1.6	0
80	Genetic Contribution to Metastatic Prostate Cancer. Urologic Clinics of North America, 2021, 48, 349-363.	1.8	0
81	Molecular Subtyping in the Neoadjuvant Setting in Prostate Cancer: Envisioning the Possibilities. European Urology, 2021, 80, 304-305.	1.9	0